Tumor necrosis factor (TNF) is a pleiotropic mediator of inflammatory responses. A cysteine-rich, highly glycosylated 30-kD TNF-binding protein (TNF-BP) purified from urine may have a role in regulation because it protects in vitro against the biological effects of TNF. The cytotoxic effect of TNF on the fibrosarcoma cell line WEHI 164 was inhibited by-50% at a 10-fold excess of TNF-BP. The binding of TNF to the receptor was partially reversed after the addition of TNF-BP. Results from biosynthetic labeling of cells with 35S-cysteine followed by immunoprecipitation with anti-TNF-BP indicated that TNF-BP is formed and released at the cell surface by cleavage because no corresponding cellular polypeptide was observed. A cellular 60-kD polypeptide, which was immunoprecipitated with anti-TNF-BP, may correspond to the transmembrane TNF-receptor molecule and be the precursor of TNF-BP. Thus, TNF-BP appears to be a soluble form of a transmembrane TNF-receptor. Moreover our results demonstrate that the production of TNF-BP is increased when the TNF receptor is downregulated in cells by treatment with TNF or by activation of protein kinase C with phorbol esters. TNF-BP may be an important agent that blocks harmful effects of TNF, and, therefore, useful in clinical applications. (J. Clin.
Introduction
Tumor necrosis factor (TNF)' produced primarily by macrophages is a pleiotropic mediator of many inflammatory responses (1) . TNF was initially recognized because of its cytotoxic and antitumor effects (2) . It was found to be identical with a factor called cachectin (3, 4) , which suppresses lipoprotein lipase and gives rise to hypertriglyceridemia of chronic inflammatory disease and malignancy (5) . TNF/cachectin is presumed to possess beneficial effects for the host by stimulation of inflammatory cells and by inhibition of viral replica- 1 . Abbreviations used in this paper: LPS, lipopolysaccharide; RIPA, radioimmunoprecipitation assay; rTNF, recombinant tumor necrosis factor, TNF, tumor necrosis factor; TNF-BP, tumor necrosis factorbinding protein.
tion and may be involved in the regulation of normal tissue homeostasis (1) . On the other hand, when the production of this cytokine is inappropriately controlled harmful manifestations occur (3) . Thus, TNF/cachetin plays a major role in the pathogenesis of gram-negative endotoxic shock (6, 7) , which can lead to cardiovascular collapse, organ failure, and death. These effects are reversed by passive immunization with anti-TNF monoclonal antibodies (6, 7) . Many, perhaps all, effects of lipopolysaccharide (LPS) are mediated by TNF/cachectin (3) . An association has been reported between the concentration of TNF in serum and fatal outcome in meningococcal disease (8) . TNF/cachectin may also be an effector of skin and gut lesions of the acute phase of graft-versus-host disease (9) .
Attempts to control the adverse effects of TNF/cachectin would be of clinical importance. We have identified a TNFbinding protein (TNF-BP) of serum and urine from patients with chronic renal failure (10) , which interferes with the binding ofTNF to its receptor and inhibits the biological activity of TNF (10) . A TNF-inhibitory activity was also described by Seckinger et al. (1 1) . We have purified TNF-BP from urine of patients with renal failure (12). TNF-BP was found to be a cysteine-rich glycoprotein with mol wt of 30 kD, without significant homologies with previously described protein sequences. Recently others have also reported the purification of a TNF inhibitor (13, 14) , which seems to be identical with TNF-BP. Because TNF-BP acts as a regulator of TNF/cachectin bioactivities it has a potential clinical application to counteract harmful manifestations such as septic shock and cachexia. In this report we describe biological and biochemical characteristics of TNF-BP and its production. The data presented suggest that TNF-BP is a soluble form of a TNF receptor released by proteolytic cleavage of the receptor at the cell surface.
Methods
Tumor necrosis Jactor (TNF) plates (Nunc 2-62170). A 50-Mi aliquot of the anti-TNF-BP antibody diluted 1:4,000 in incubation buffer (0.1 mol/liter NaCl, 0.05 mol/liter NaH2PO4, 0.05% Tween-20, adjusted to pH 7.5 with NaOH) was added to each well followed by overnight incubation at 4°C to allow equilibration between TNF-BP and anti-TNF-BP. In parallel, 96-well flat-bottom immunoplates (Nunc 4-39445) were coated with TNF-BP, 100 jl/well diluted to 7.5 ng/ml in 0.1 mol/liter NaHCO3, and incubated overnight at room temperature followed by three washes in washing solution (0.15 mol/liter NaCl, 0.05% Tween-20). The content of the sample plate was transferred to the plate coated with TNF-BP which was incubated for 3 h at 4°C to allow binding of free anti-TNF-BP antibodies to immobilized TNF-BP and washed three times. For detection of bound anti-TNF-BP antibodies, an aliquot of 100 1l secondary antibody, diluted 1:200 in incubation buffer supplemented with 1 mg/ml bovine serum albumin was added to each well. The secondary antibody was goat anti-rabbit antibody conjugated to biotin (Vectastain ABC kit, AK-500 1, Vector Laboratories, Inc., Burlingame, CA). The plates were incubated for 1 h at room temperature followed by three washes. To increase the absorbance and thereby the sensitivity, 100 Ad of a solution containing avidin-biotin (Vectastain ABC kit, AK-5001) was added to each well followed by incubation ofthe plates for 1 h, washing, and addition of phosphatase substrate (Sigma 104) dissolved in I mol/liter diethanolamine buffer, pH 9. Digestion with N-glycanase. '251-TNF-BP was deglycosylated with N-glycanase (Genzyme Corp., Boston, MA) according to the manufacturer's description. TNF-BP was denaturated by boiling 4 min in 0.1 M fl-mercaptoethanol and 0.5% SDS. The sample was diluted to a final concentration of 0.2 mol/liter sodium phosphate pH 8.6, 10 mmol/ liter 1, 10-phenantroline hydrate and 1.25% NP-40. N-Glycanase was added (0.08-10 U/ml) followed by incubation at 37°C for 4 h. Controls were incubated without N-glycanase.
Results
Stochiometry ofthe binding between TNF-BP and rTNF. The complex formation between TNF-BP and rTNF was analyzed by gel chromatography. TNF-BP and rTNF were eluted from a Sephacryl S-200 column corresponding to molecular weights of 50 and 35 kD, respectively (Fig. 1) . In its active form TNF is thought to be trimeric (19) and it might have been retarded on the column because of adsorption. Mixtures of equimolar amounts of '25I-TNF-BP and rTNF were chromatographed and all radioactivity was found to be associated with a complex that had an apparent molecular weight of 65 kD (Fig. 1) . It is not possible to conclude from these results whether TNF bound to TNF-BP as a trimer, dimer, or monomer.
The binding between TNF-BP and TNF was highly susceptible to low pH. No binding was observed at pH 5.0 or below (Fig. 2) . The binding was also susceptible to reduction because it was abolished in the presence of 1.25% 2-mercaptoethanol (data not shown). 50% reduction of the TNF effects is observed at approximately a 10-fold molar excess of TNF-BP.
The specific binding of '251I-rTNF to the surface of HL-60 cells was partially reversed by TNF-BP. Cells were incubated with '25I-rTNF for 2 h after which TNF-BP was added. A dose-dependent decrease of specific rTNF binding was observed (Fig. 4) . Experiments were also performed to investigate if antibodies to TNF-BP bound to cells and interferred with TNF binding to cell surface receptor. Actually preincubation of HL-60 cells with anti-TNF-BP inhibited to -40% the specific binding of 125I-rTNF (Fig. 4) .
Deglycosylation of TNF-BP. When TNF-BP was treated with N-glycanase, its molecular weight was reduced from 31 to (Fig. 5) . N-Glycanase cleaves N-linked oligosaccharides independent of type. These results demonstrate the presence of a high carbohydrate content. In addition, partial digestion with N-glycanase shows three separate cleavage products consistent with the presence of at least three glycosylation sites (Fig. 5) .
Biosynthesis of TNF-BP. The finding of inhibition of 125j1 rTNF binding to cells by antibodies to TNF-BP suggested an homology between TNF-BP and TNF receptor. Therefore, experiments were performed to immunoprecipitate TNF-BP produced by biosynthetically-labeled cells.
TNF-BP was biosynthetically labeled with 35S-cysteine because of its high cysteine content (12). Several polypeptides were immunoprecipitated with anti-TNF-BP from HL-60 cell lysates and had molecular weights of -60, 45, 42, and 40 kD (Fig. 6 ). Apparently none of these corresponded to the intact TNF-BP molecule. However, when the label was chased and then followed by immunoprecipitation of the cell supernatant with anti-TNF-BP, a labeled polypeptide presumably mature TNF-BP appeared (Fig. 6) . It is likely that the cellular components specifically precipitated with anti-TNF-BP represent precursor forms for TNF-BP. The 60-kD polypeptide may correspond to the transmembrane TNF-receptor molecule, whereas the other components as well as mature TNF-BP may represent cleavage products ofthe receptor. Fig. 6 also demonstrates that incubation of cells with PMA results in a large increase in the production ofextracellular TNF-BP. This effect was most probably mediated by activation of protein kinase C because 4 a-PMA, which does not activate protein kinase C, did not increase production of TNF-BP (data not shown). No mature TNF-BP polypeptides could be detected in extracts of PMA-treated HL-60 cells (Fig. 6) . Thus, it is likely that the mature TNF-BP molecule is formed at the cell surface followed by its immediate release. The time course for production of TNF-BP in "S-labeled HL-60 cells treated with PMA is shown in Fig. 7 . Further, it was observed that TNF itself induced production of TNF-BP (Fig. 7) .
Also results from biosynthetic labeling of other cell lines supported the above notions. Immunoprecipitation with anti- revealed in particular an Mr 60-kD polypeptide, which may correspond to the intact transmembrane TNF receptor molecule (Fig. 8) . Additional polypeptides were immunoprecipitated from cell lysates with molecular weights of 40 and 37 kD, which may represent cleavage products ofthe receptor. As for HL-60 cells none of these cellular polypeptides corresponded to TNF-BP, but chase of the label in the presence of PMA resulted in the occurrence of labeled TNF-BP in the cell supernatant (Fig. 8) . In addition to TNF-BP, an extracellular Mr 34-kD polypeptide that was absent from cell lysates was also released and reacted with anti-TNF-BP. The latter may represent another cleavage product of the transmembrane TNF receptor, which is released extracellularly. Production ofTNF-BP by HL-60 cells was also determined by an ELISA. Both rTNF and recombinant lymphotoxin induced TNF-BP production during incubation for 4 d (Fig. 9 ). An increased production of TNF-BP was visible after 2 d. It is possible that the production of TNF-BP correlates with the TNF-and lymphotoxin-induced differentiation of HL-60 cells. However, biosynthetically labeled TNF-BP was detected to be released from cells within 20 h of incubation with TNF.
On a molar basis, lymphotoxin seemed to be more efficient than TNF. The optimal concentration was -1,000 pmol/liter for both lymphotoxin and TNF.
TNF-BP was detected in the supernatant ofa large number ofcell lines, mononuclear blood cells, neutrophil granulocytes, and fibroblasts (data not shown). The production of TNF-BP was generally increased by incubation with PMA. 
Discussion
In the present study, we report characteristics of a TNF binding protein purified to homogeneity from urine of patients with renal failure (12). The amino-terminal amino acid sequence has not revealed significant homologies with previously described protein sequences. Analysis by SDS-PAGE has shown that TNF-BP is composed of a single polypeptide chain with an apparent Mr of 30 kD (12), but it was eluted from a gel filtration column corresponding to a molecular weight of 50 kD. Perhaps TNF-BP forms a dimer at nondenaturing conditions or has a high excluded volume because of its high carbohydrate content. Analysis of immunoprecipi- tated TNF-BP by SDS-PAGE showed that the molecular weight of TNF-BP was reduced from 30 to 21 kD by treatment with N-glycanase, whereas results from partial digestion with N-glycanase suggested that TNF-BP had at least three N-linked oligosaccharide side chains. We could not establish whether TNF-BP binds to the trimeric form of TNF, which is the biologically active form (19 (28) . Also, other cytokine receptors may be released into body fluids including soluble receptors for both interleukin-6 and interferon-y detected in urine (29) . In addition, activation of protein kinase C by phorbol esters has been shown to induce proteolytic cleavage of the CSF-1 receptor in its extracellular domain at a site near the membrane-spanning sequence (30) . This form of transmodulation, possibly due to activation of a protease, may occur with several different cell surface receptors and serve to regulate the inflammatory response.
TNF and LT are internalized through receptor-mediated endocytosis and the ligand is degraded in lysosomes (31, 32) . We assume that binding of TNF to TNF-BP imitates receptor binding of TNF. Many receptor-ligand complexes are dissociated after internalization into receptosomes. The complex formed between TNF and TNF-BP was highly sensitive to low-pH environment and completely dissociated at pH 5.0 or lower. If this result is relevant to binding of TNF to a receptor, then dissociation of the ligand-receptor complex in receptosomes may be due to acidity.
In this study we also demonstrate an increased production of TNF-BP from cells under conditions which favor downregulation of the TNF receptor. A spontaneous turnover of the TNF receptors has been reported with a half life of -2 h (24, 33, 34). Agents which activate protein kinase C such as PMA and diacylglycerol l-oleoyl-2-acetyl-glycerol, downregulate the TNF receptor (32, 33) . Also, TNF itself has been shown to downregulate its receptor (24, 35) . A receptor occupancy above a certain level resulted in downregulation that persisted for a prolonged time period (24). The production of TNF-BP from HL-60 cells was activated when TNF receptor was downregulated by PMA or rTNF. IfTNF-BP is a soluble cleavage fragment of a TNF receptor the results imply that agents like PMA and TNF induce cleavage of the transmembrane receptor with release of TNF-BP by activation of a protease. Alternatively, PMA and TNF may induce de novo synthesis of an active protease. However, the production ofTNF-BP by the cells was prolonged and would imply that downregulation of a receptor for TNF also initiated new synthesis of receptor with continuous formation of TNF-BP. There is evidence for development of tolerance to the toxic effect of TNF after exposure to TNF itself (36, 37) , indicating that effects of TNF can be modulated by antagonistic mechanisms. One explanation could be the production ofTNF-BP. Our finding ofa release of TNF-BP during conditions when the receptor is downregulated (e.g., by TNF itself) may provide an explanation for the protection against deleterious effects of TNF induced by TNF itself. It still remains to show whether TNF-BP can function as an antagonist to TNF in vivo. If this occurs, it might contribute to the elimination of TNF.
In conclusion we have characterized a TNF binding protein purified to homogeneity from urine. The evidence available suggests that TNF-BP is a soluble form ofa TNF receptor. Our results also show that the production of TNF-BP is increased when TNF receptor is downregulated with TNF itself or with phorbol ester. Responses to endotoxinemia can be explained by the synthesis of TNF, which is a central mediator of host response to bacterial infection and inflammation. Therefore, TNF-BP could have clinical importance in neutralizing harmful manifestations of TNF/cachectin.
